| abstract |
The present invention provides erythropoietin-responsive cells in vivo, in situ or ex vivo by mammalian (including human) by systemically or locally administering an erythropoietin receptor activity modulator such as erythropoietin or modified erythropoietin. Methods and compositions are provided that protect or enhance the function or survival of tissues, organs or body parts. |